Targeted Plasticity Therapy for PTSD

Официальное название

Targeted Plasticity Therapy for the Treatment of Post-Traumatic Stress Disorder

Обзор

Objectives of this study are to provide continued safety assessment for the ReStore system, and to gain further estimates of the effect size of Vagus Nerve Stimulation (VNS) therapy with Prolonged Exposure Therapy (PE) compared to PE with placebo (sham) stimulation in participants with posttraumatic stress disorder (PTSD)

Подробное описание

A prospective, multi-center, randomized, controlled, blinded trial of participants implanted with the ReStore Device for VNS Therapy.

In double-blinded Phase 1, after implantation, participants will be randomized to either active VNS stimulation or sham VNS stimulation, accompanying PE therapy twice weekly for 7 weeks (12 in-office sessions, Phase 1). The therapist and the participant will be blinded of the group assignment.

Following completion of Phase 1, all participants undergo two mid-therapy assessments and then advance to the open-label Phase 2.

In open-label Phase 2, all participants will receive up to an additional 12 sessions of PE therapy paired with active VNS stimulation, regardless of their prior assignment in Phase 1.

Post-therapy assessments will be performed 1 day, 1 month, and 6 months following the completion of the final session of PE in Phase 2.

During the in-office sessions, the therapist will use a secure smart device to deliver stimulation and record audio of the session for use during homework sessions. The smart device will automatically trigger VNS during audio homework sessions at the same times that the therapist delivered VNS during the corresponding in-office session.

Long-term assessment of safety will be performed up to four times annually for up to 2 years following the date of implant or until the device is FDA approved when possible. Safety assessment will only report on the presence of the implanted, non-active device and/or participant status during this period. Participants who experience a serious device-related adverse event will be removed from the identified risk but will continue to be monitored for 2 years or longer if the event has not resolved.

Вмешательства

• Устройство Active VNS stimulation
  The subjects in this group will be implanted with the ReStore device and receive active Vagus nerve stimulation (VNS) in phase 1
• Устройство Sham VNS stimulation
  The subjects in this group will be implanted with the ReStore device and receive sham Vagus nerve stimulation (VNS) in phase 1

Первичные конечные точки

• ReStore System Safety [Срок оценки: From surgery to up to 2 years following implantation or until the device is FDA approved, whichever comes first]

Вторичные конечные точки (5)

• Clinician Administered PTSD Scale for DSM-5(fifth edition of the Diagnostic and Statistical Manual of Mental Disorders)(CAPS-5) [Срок оценки: From baseline up to visit 33 (end of study)]
• PTSD Checklist for DSM-5 (PCL-5) score [Срок оценки: From baseline up to visit 33 (end of study)]
• PostTraumatic Cognitions Inventory (PTCI) [Срок оценки: From baseline up to visit 33 (end of study)]
• Generalized Anxiety Disorder 7-item Scale (GAD-7) [Срок оценки: From baseline up to visit 33 (end of study)]
• Patient Health Questionnaire-9 (PHQ-9) [Срок оценки: From baseline up to visit 33 (end of study)]

Критерии участия

Критерии включения

• Diagnosis of chronic PTSD for at least 3 months based on DSM-5 criteria
• In the medical opinion of the Principal Investigator (PI), failed at least one adequate course of first-line PTSD treatment per American Psychological Association (APA) guidelines
• PCL-5 score greater than 33
• Age 22-79 years
• Appropriate surgical candidate for VNS device implantation
• Willing and able to comply with study protocol
• Able to provide informed consent.

Критерии исключения

• Currently undergoing prolonged exposure therapy elsewhere
• Concurrent participation in another interventional clinical trial
• Prior injury to vagus nerve
• Prior or current treatment with vagus nerve stimulation
• Psychiatric disorders and/or cognitive impairments that would interfere with study participation, as assessed by medical evaluation
• Moderate-High Risk of Suicide according to Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version
• Persons with a current or past: (a) medical (psychiatric, non-psychiatric) condition, disease, disorder, injury, or disability or (b) non-medical situation or circumstance that, in the opinion of the principal investigator, study participation:

• may pose a significant or undue risk to the person,
• make it unlikely the person will complete all the study requirements per protocol, or
• may adversely impact the integrity of the data or the validity of the study results
• Persons with a neck circumference larger than 18.5 inches
• Females of childbearing potential who are either pregnant or planning to become pregnant and who are not using, or will not agree to use medically acceptable birth control methods
• Non-English speaking
• As determined by the principal investigator, is under current incarceration or legal detention

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

США · 3 центра

• The University of Texas Health Austin Ambulatory Surgery Center — Austin
• Baylor University Medical Center — Dallas
• Texas Biomedical Device Center — Richardson

Идентификаторы

NCT: NCT06266364 · IRB-24-22 · HT94252310818 · 175181

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗